Top 50 Biotech Startup Investors in Europe (October 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
SOSV
VC Fund
|
185 | United States, China, Canada | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | $50k–$5M |
|
Bpifrance
VC Fund
|
131 | France, United States, Switzerland | Seed, Venture - Series Unknown, Series A | Software, Health Care, Biotechnology | $752k–$34M |
|
HTGF (High-Tech Gruenderfonds)
VC Fund
|
88 | Germany, Switzerland, United States | Seed, Series A, Pre-Seed | Software, Biotechnology, Information Technology | $790k–$31M |
|
Sofinnova Partners
VC Fund
|
83 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $7M–$105M |
|
UK Innovation & Science Seed Fund
VC Fund
|
70 | United Kingdom, United States | Seed, Venture - Series Unknown | Biotechnology, Health Care, Medical | $582k–$6.7M |
|
Parkwalk Advisors
VC Fund
|
66 | United Kingdom, United States, Philippines | Seed, Series A, Series B | Biotechnology, Health Care, Software | $991k–$44M |
|
Scottish Enterprise
VC Fund
|
63 | United Kingdom, United States, Switzerland | Grant, Seed, Venture - Series Unknown | Biotechnology, Software, Health Care | $119k–$8.4M |
|
Novo Holdings
VC Fund
|
58 | United States, Denmark, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $9.5M–$135M |
|
Future Planet Capital
VC Fund
|
55 | United Kingdom, United States, Singapore | Seed, Convertible Note | Biotechnology, Health Care, Software | $670k–$5.1M |
|
Oxford Science Enterprises
VC Fund
|
53 | United Kingdom, United States, Finland | Seed, Series A, Series B | Health Care, Biotechnology, Medical | $1.3M–$168M |
|
SFC Capital
VC Fund
|
52 | United Kingdom, United States, Ireland | Seed, Pre-Seed, Venture - Series Unknown | Software, Artificial Intelligence, Information Technology | $123k–$2.5M |
|
Enterprise Ireland
VC Fund
|
47 | Ireland, United States, United Kingdom | Seed, Venture - Series Unknown, Grant | Software, Health Care, Information Technology | $26k–$8.3M |
|
Seventure Partners
VC Fund
|
47 | France, United States, Germany | Series A, Series B, Seed | Biotechnology, Software, Health Care | $1.1M–$63M |
|
Kurma Partners
VC Fund
|
43 | France, Switzerland, The Netherlands | Series A, Seed, Series B | Health Care, Biotechnology, Pharmaceutical | $2.8M–$98M |
|
Entrepreneurs First
VC Fund
|
40 | United Kingdom, Singapore, United States | Seed, Pre-Seed, Series A | Artificial Intelligence, Software, Machine Learning | $54k–$41M |
|
Scottish Investment Bank
VC Fund
|
40 | United Kingdom, United States, France | Venture - Series Unknown, Seed, Series A | Software, Biotechnology, Health Care | $199k–$7.5M |
|
Inveready
VC Fund
|
37 | Spain, United States, France | Seed, Venture - Series Unknown, Debt Financing | Software, Biotechnology, Health Care | $400k–$6.5M |
|
Oxford Technology Management
VC Fund
|
37 | United Kingdom, United States | Seed, Series A | Biotechnology, Health Care, Software | $33k–$8.5M |
|
Boehringer Ingelheim Venture Fund
VC Fund
|
36 | United States, Germany, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $1.8M–$50M |
|
Almi Invest
VC Fund
|
34 | Sweden, Norway, United States | Venture - Series Unknown, Seed | Software, Health Care, Information Technology | $226k–$3.5M |
|
Jonathan Milner
Angel
|
34 | United Kingdom, United States, Spain | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $537k–$56M |
|
Centre for the Development of Industrial Technology (CDTI)
VC Fund
|
33 | Spain, United States, United Kingdom | Grant, Seed, Venture - Series Unknown | Biotechnology, Health Care, Software | $167k–$26M |
|
O2h Ventures
VC Fund
|
33 | United Kingdom, Hungary | Seed, Venture - Series Unknown, Series A | Biotechnology, Health Care, Pharmaceutical | $603k–$25M |
|
IP Group
VC Fund
|
31 | United Kingdom, United States, Australia | Seed, Series A, Series B | Biotechnology, Health Care, Information Technology | $208k–$68M |
|
BioInnovation Institute
VC Fund
|
31 | Denmark, Germany, Switzerland | Convertible Note, Pre-Seed, Seed | Biotechnology, Medical, Health Care | $495k–$5.2M |
|
Portugal Ventures
VC Fund
|
30 | Portugal, United States, United Kingdom | Seed, Venture - Series Unknown, Pre-Seed | Software, Information Technology, Health Care | $107k–$3.6M |
|
SOSV SF & NY (Fka IndieBio)
VC Fund
|
30 | United States, United Kingdom, Canada | Seed, Pre-Seed, Convertible Note | Biotechnology, Health Care, Medical | $50k–$5M |
|
Forbion Capital Partners
VC Fund
|
29 | United States, United Kingdom, The Netherlands | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $16M–$180M |
|
Mercia Fund Managers
VC Fund
|
29 | United Kingdom, United States, Hungary | Seed, Venture - Series Unknown, Series A | Software, Health Care, Biotechnology | $250k–$14M |
|
Chalmers Ventures AB
VC Fund
|
29 | Sweden, United States | Pre-Seed, Seed, Venture - Series Unknown | Software, Biotechnology, Information Technology | $5.8k–$3.5M |
|
GO CAPITAL
VC Fund
|
29 | France, Canada, Israel | Seed, Venture - Series Unknown, Series A | Software, Biotechnology, Health Care | $549k–$13M |
|
Business Growth Fund
VC Fund
|
28 | United Kingdom, Ireland, United States | Venture - Series Unknown, Private Equity, Series A | Software, Manufacturing, Information Technology | $3.4M–$22M |
|
European Investment Bank
VC Fund
|
27 | France, Germany, Italy | Debt Financing, Post-IPO Debt, Venture - Series Unknown | Energy, Biotechnology, Health Care | $8.7M–$587M |
|
Epidarex Capital
VC Fund
|
27 | United Kingdom, United States, Germany | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $551k–$48M |
|
Catapult Ventures
VC Fund
|
27 | United Kingdom, United States, Israel | Seed, Venture - Series Unknown | Health Care, Biotechnology, Medical | $150k–$5.6M |
|
Meusinvest (Noshaq)
VC Fund
|
27 | Belgium, France, Germany | Series A, Seed, Venture - Series Unknown | Biotechnology, Health Care, Medical | $137k–$16M |
|
Development Bank of Wales
VC Fund
|
27 | United Kingdom, Australia, United States | Seed, Debt Financing, Venture - Series Unknown | Software, Health Care, Manufacturing | $19k–$5.5M |
|
SOSV HAX
VC Fund
|
26 | United States, Canada, China | Seed, Convertible Note, Pre-Seed | Robotics, Manufacturing, Health Care | $25k–$4.7M |
|
Northstar Ventures
VC Fund
|
26 | United Kingdom, United States, Indonesia | Seed, Venture - Series Unknown, Series A | Software, Health Care, Information Technology | $46k–$10M |
|
Idinvest Partners
VC Fund
|
26 | France, United States, Germany | Series A, Series B, Venture - Series Unknown | Software, Health Care, Biotechnology | $3.4M–$66M |
|
Karista
VC Fund
|
26 | France, United States, Finland | Seed, Series A, Series B | Software, Biotechnology, Health Care | $768k–$33M |
|
Elaia
VC Fund
|
25 | France, United States, Spain | Seed, Series A, Series B | Software, Artificial Intelligence, Information Technology | $1.1M–$50M |
|
M Ventures
VC Fund
|
25 | United States, United Kingdom, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.4M–$100M |
|
Syncona Partners LLP
VC Fund
|
25 | United Kingdom, United States, Switzerland | Series A, Series B, Seed | Biotechnology, Medical, Health Care | $1.9M–$156M |
|
Kelvin Capital
VC Fund
|
24 | United Kingdom, United States | Seed, Venture - Series Unknown | Health Care, Biotechnology, Manufacturing | $167k–$4.5M |
|
CDP Venture Capital
VC Fund
|
24 | Italy, United States, Switzerland | Seed, Series A, Venture - Series Unknown | Software, Artificial Intelligence, Health Care | $483k–$23M |
|
Archangels
VC Fund
|
24 | United Kingdom, United States | Venture - Series Unknown, Seed | Software, Health Care, Biotechnology | $867k–$6.6M |
|
PMV
VC Fund
|
24 | Belgium, United States, The Netherlands | Seed, Series A, Series B | Software, Biotechnology, Health Care | $1M–$43M |
|
Invivo Capital Partners
VC Fund
|
23 | Spain, France, Belgium | Seed, Series A, Venture - Series Unknown | Biotechnology, Pharmaceutical, Health Care | $1.6M–$70M |
|
Octopus Ventures
VC Fund
|
23 | United Kingdom, United States, Germany | Series A, Seed, Series B | Software, Artificial Intelligence, Health Care | $2.1M–$43M |
| Access all 50 investors in Europe Biotech startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
SOSV offers pre-seed capital and follow-on financial support to startups focusing on deep technology and scientific innovation. Founders utilize purpose-built laboratory facilities and engineering spaces to accelerate product development and testing. The firm facilitates connections between entrepreneurs and a network of investors through structured matchmaking events and technology summits.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, China, Canada
Investor stats
- Total investments: 3729
- Round size: Seed $150k–$5M; Pre-Seed $50k–$1.6M; Convertible Note $50k–$3.6M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely still investing — raised $306M in 2023
Portfolio highlights
- Halla — Halla Intelligence is a digital solution that leverages over 100 billion shopper and product data points to recommend and promote what grocery items.
- Simply Good Jars — Simply Good Jars is a B-Corp company that delivers healthy meals in reusable + returnable packaging through use of smart refrigerated kiosks placed in offices, transit centers, universities and health-systems. Driven by purpose to change that way people think about consumption, SGJ introduces sustainable business practices into their everydayoperations with a zero-waste goal. For every jar returned back to the company for reuse, they will help feed someone in need and ensure that no packaging materials end up in landfills.
- Verdex Technologies — Verdex Technologies is an advanced materials platform technology that uses nanofibers to disrupt industries. Verdex doesn't just compete, it innovates and disrupts.
Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Venture - Series Unknown, Series A
- Geography: France, United States, Switzerland
Investor stats
- Total investments: 1723
- Round size: Seed $752k–$6.1M; Series A $2.6M–$34M; Venture - Series Unknown $1.1M–$32M
- Lead/follow: 27% lead, 73% follow
- Last fund: Likely actively investing — fresh fund, raised $27M in 2025
Portfolio highlights
- Melvan — Melvan develops, finances, builds and operates solar and wind installations, combined, where relevant, with storage facilities.
- WAAT — WAAT operates fast charging stations for electric and rechargeable hybrid vehicles. Its services are aimed at all private sector market segments, including condominiums, lessees, tertiary, and real estate development. The company was founded in 2018 and is based in Paris with sales offices in Malakoff and Bagneux (92).
- Nepsis — AI-powered software and debt advisory for renewable energy developers. Modern financing solutions for small & medium renewable projects.
High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in various sectors.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Series A, Pre-Seed
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 781
- Round size: Seed $790k–$6.9M; Pre-Seed $841k–$2.8M; Series A $3M–$31M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely still investing — raised $515M in 2022
Portfolio highlights
- Selfapy — Selfapy offers a therapy support tool that helps recognize negative patterns of thought and train new behavior. Selfapy is your guided, self-help online course against depression with a personal psychologist as a companion.
- Smartblue — Smartblue develops and runs software and processes to monitor and optimize zero emission energy systems. As a hardware independent specialist Smartblue delivers a software service for the maintenance, life-cycle management, production forecasting and remote control of photovoltaic and energy storage systems all together in one centralized “SmartControl” Operations and Control Center web application. We help our customers drive down overall operational cost through automation, smart failure detection and big data analysis on imminent defects.
- OMEICOS Therapeutics — OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activatean endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 353
- Round size: Series A $7M–$70M; Series B $10M–$105M; Series C $12M–$100M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely actively investing — fresh fund, raised $755M in 2025
Portfolio highlights
- Odoo — From ERP to CRM, eCommerce and CMS. Download Odoo or use it in the cloud. Grow Your Business.
- HighLife — HighLife is driven by a mission to deliver innovative treatment options to patients suffering from heart valve diseases.
- EnginZyme — Enzymatic chemistry for cleaner ingredients in personal care, food and pharma. Enginzyme's patented EziG platform makes enzymes work at industrial scale.
UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Venture - Series Unknown
- Geography: United Kingdom, United States
Investor stats
- Total investments: 151
- Round size: Seed $582k–$5.9M; Venture - Series Unknown $1M–$6.7M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — last raise in 2014
Portfolio highlights
- Zentraxa — NATURE ENGINEERED FOR PURPOSE Through millions of years of evolution, nature has found solutions to the most difficult problems. Inspired by the diversity of nature, we precision engineer bespoke biomaterials to meet the toughest challenges across
- StandardX — StandardX is a deep-tech company building the isotope refinery powered by a scalable, compact particle accelerator platform.
- SILVIA BIO — SilVia Bio develops technologies to analyze and optimize mammalian cell factories used in biomanufacturing. The company focuses on identifying critical parameters that limit bioproduction yield and product quality in cell systems such as CHO and HEK cells. Its platform provides cell profiling services that generate interpretable data on manufacturing-relevant bottlenecks. Based on these insights, SilVia Bio designs and supplies precision media additives formulated to address specific rate-limiting cellular processes. The offerings are intended for biopharmaceutical and biomanufacturing teams seeking to improve titre, cell performance, and consistency in production processes. SilVia Bio also collaborates with industrial partners to apply its platform within real manufacturing environments.
Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009, anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth. Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Philippines
Investor stats
- Total investments: 338
- Round size: Seed $991k–$4.9M; Series A $1.6M–$14M; Series B $1.8M–$44M
- Lead/follow: 27% lead, 73% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- K3 Metrology — K3 Metrology is a specialist metrology company commercialising laser‑based 3D coordinate measurement technology developed at the National Physical Laboratory. The company’s platform is designed to provide high‑accuracy, uncertainty‑aware dimensional data in large‑volume industrial environments, supporting inspection and assembly processes inadvanced manufacturing. Its systems integrate into production workflows where traceable measurements are required across complex geometries and large structures. The technology is applied in sectors such as aerospace, defence, and nuclear, where dimensional integrity and process control are critical.
- MoA Technology — We harness the principles of natural selection to accelerate discovery for better, safer herbicides so farmers can continue to feed the world.
- Quantum Motion — Quantum Motion delivers scalable silicon-based quantum computing using standard semiconductor manufacturing technology.
Scotland's business advice, support and funding agency. Explore our products and services to find the right support for your business and apply online today.
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Grant, Seed, Venture - Series Unknown
- Geography: United Kingdom, United States, Switzerland
Investor stats
- Total investments: 403
- Round size: Seed $387k–$4.3M; Grant $119k–$4.8M; Venture - Series Unknown $681k–$8.4M
- Lead/follow: 37% lead, 63% follow
Portfolio highlights
- CSignum — Revolutionising underwater communications with electromagnetic technology for seamless data integration between surface & submerged devices.
- GLORIAH — Nurse founded, natural intimate hydration oils and gels for menopause.
- SolarSub — SolarSub is an environmental firm that offers floating solar cooling system.
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 409
- Round size: Series A $9.5M–$133M; Series B $15M–$135M; Series C $30M–$118M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $165M in 2018
Portfolio highlights
- IVERIC bio — IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inheritedretinal diseases.
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- SCHOTT Poonawalla — SCHOTT Poonawalla is a manufacturer of pharmaceutical containers, made of neutral glass tubing. The company provides parenteral packaging systems crafted from tubular glass, serving the pharmaceutical industry with a broad range of products including vials, pre-fillable syringes, ampoules, and cartridges.
Brilliant Ideas. Brilliant People. Brilliant Minds.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note
- Geography: United Kingdom, United States, Singapore
Investor stats
- Total investments: 289
- Round size: Seed $670k–$5.1M
- Lead/follow: 4% lead, 96% follow
- Last fund: Likely still investing — raised $23M in 2022
Portfolio highlights
- Unloq AI — Unloq is a Decision Intelligence Platform that turns your company data and live market signals into governed strategic recommendations. Approved, tracked, measured.
- Nourished — At Nourished we create innovative. personalised nutrition stacks that are truly unique to you. Vegan, waste-free and always made to order.
- K3 Metrology — K3 Metrology is a specialist metrology company commercialising laser‑based 3D coordinate measurement technology developed at the National Physical Laboratory. The company’s platform is designed to provide high‑accuracy, uncertainty‑aware dimensional data in large‑volume industrial environments, supporting inspection and assembly processes inadvanced manufacturing. Its systems integrate into production workflows where traceable measurements are required across complex geometries and large structures. The technology is applied in sectors such as aerospace, defence, and nuclear, where dimensional integrity and process control are critical.
Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking on challenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Finland
Investor stats
- Total investments: 210
- Round size: Seed $1.3M–$12M; Series A $6.3M–$45M; Series B $9.1M–$168M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely still investing — raised $299M in 2022
Portfolio highlights
- Salience Labs — Salience Labs is building a hybrid photonic-electronic chip for AI. We have designed a massively parallel, ultra-high-throughput Photonic Tensor Processing Unit. Photonics allows data to be modulated at up to 100 GHZ, and allows for high levels of parallelization using multiplexing. We integrate this photonic unit into a SoC architecture designedto exploit its high throughput for AI inference. Salience Labs technology is based on decades of research collaboration between Oxford University and the University of Münster, Germany.
- OMass Therapeutics — OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics against challenging disease targets.
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Discover the UK's leading SEIS Fund, offering tax-efficient investments in innovative startups. Join thousands of savvy investors and raise capital for your business with SFC Capital.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Pre-Seed, Venture - Series Unknown
- Geography: United Kingdom, United States, Ireland
Investor stats
- Total investments: 786
- Round size: Seed $123k–$2M; Pre-Seed $170k–$858k; Venture - Series Unknown $201k–$2.5M
- Lead/follow: 36% lead, 64% follow
- Last fund: May invest from a new fund soon — raised $1.9M in 2019
Portfolio highlights
- Obsero — Obsero is an AI search intelligence platform and consultancy designed for marketing and communications teams. The platform tracks, measures, and optimizes how brands surface, get cited, and are recommended across Large Language Models (LLMs) and AI search assistants.
- SolarSub — SolarSub is an environmental firm that offers floating solar cooling system.
- NEARHUMAN — Nearhuman develops intelligent safety systems for micromobility and other physical-world devices. The company focuses on edge AI and computer vision that run directly on vehicles such as e-scooters and e-bikes to detect hazards, monitor pedestrian proximity, and support real-time decision making. Its flagship product, Scootrr, is an AI-powered safety platform that enables on-device perception, automatic deceleration, and safety analytics without reliance on cloud connectivity. Nearhuman designs its technology to integrate with existing shared micromobility fleets, collaborating with operators, vehicle manufacturers, and research partners. The company also provides dashboards and tools that turn on-vehicle events into route-level safety intelligence for stakeholders such as fleet operators and city authorities. Its work spans hardware vision kits, embedded firmware, perception models, and supporting software for deployment and monitoring.
Enterprise Ireland is the government agency responsible for the development and funding of the indigenous business sector. Their mission is to accelerate the development of companies to achieve strong positions in global markets resulting in increased national and regional prosperity. It was founded in 1998 and headquartered in Dublin, Ireland.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Seed, Venture - Series Unknown, Grant
- Geography: Ireland, United States, United Kingdom
Investor stats
- Total investments: 894
- Round size: Seed $394k–$3.2M; Grant $26k–$5.5M; Venture - Series Unknown $560k–$8.3M
- Lead/follow: 29% lead, 71% follow
- Last fund: May invest from a new fund soon — raised $1.2M in 2021
Portfolio highlights
- Foodcloud — We connect businesses that have surplus food with Charities and Community Groups that need it.
- Amethyst Care — Amethyst Care is a startup that creates an AI-powered voice assistant for those with mobility difficulties.
- Full Health Medical — Full Health Medical patient empowerment tools that improve prevention healthcare are part of the healthcare ecosystem. FHM provides reliable digital innovation, designed by healthcare professionals that are keen to help patients live a healthy life, in response to a national scarcity of healthcare providers, the development of chronic disease, anda lack of transparency at the patient level. People provide lifetime access to preventive care healthcare across screening, diagnostics, education, treatment, and a record of their journey driven technology provides lifetime access to preventative healthcare custom designed at every step screening, diagnostics, education, and action plans that motivate individuals to address risks before they develop health problems.
Seventure Partners is a French venture capital firm targeting in Tech/Digital and Life Sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion. Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with € 1 billion under management as of December 31, 2023. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations. Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors. The different funds/verticals on which Seventure Partners are focusing on today: - Life Sciences : Biotech, Healthcare, Nutrition - Tech/Digital : B2B SaaS, Fintech, Retailtech, Cybersecurity - Sports & Wellbeing - Blue Economy
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Series A, Series B, Seed
- Geography: France, United States, Germany
Investor stats
- Total investments: 275
- Round size: Seed $1.1M–$4.7M; Series A $3.2M–$28M; Series B $3.4M–$63M
- Lead/follow: 38% lead, 62% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Ekstere — Ekstere facilitates selling and purchasing verified-quality used bicycles at a reasonable price.
- Presto Engineering — We enable companies imagine and implement microelectronics solutions in high-value markets such as Industrial, Automotive, Communication and Medical.
- Kainova Therapeutics — Domain Therapeutics is a biopharmaceutical company focused on GPCR in immuno-oncology. Discover more than you think on our innovative cancer treatments tackling GPCR mediated-immunosuppression
Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovations in Europe, particularly through links with many institutes. research and prestigious hospitals.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Pharmaceutical
- Stage:Series A, Seed, Series B
- Geography: France, Switzerland, The Netherlands
Investor stats
- Total investments: 146
- Round size: Seed $2.8M–$14M; Series A $3.9M–$98M; Series B $12M–$72M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely still investing — raised $236M in 2024
Portfolio highlights
- RougeTx — RougeTx is a Netherlands-based biotech developing first-in-class small-molecule therapies for vascular diseases caused by pericyte dysfunction. Its lead candidate, RTX-001, targets hereditary haemorrhagic telangiectasia (HHT), an inherited disorder involving fragile blood vessels and recurrent bleeding.
- AM Pharma — AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derivedpeptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
- Nuclidium — NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics.
We turn exceptional individuals into funded founders. We back you first, then give you a bridge to Silicon Valley.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Machine Learning
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, Singapore, United States
Investor stats
- Total investments: 485
- Round size: Seed $54k–$6.7M; Pre-Seed $55k–$2.7M; Series A $5.1M–$41M
- Lead/follow: 24% lead, 76% follow
- Last fund: Likely actively investing — fresh fund, raised $133M in 2026
Portfolio highlights
- ByteAsk — Derisk your AI agents
- Sourcepulse — Your early warning system for software delivery (YC S23)
- Open Cosmos — Open Cosmos design, build and operate space missions, providing straightforward access to high quality satellite data and insights on a global scale.
Speak with our team, who can help you find sources of finance, engage with funders and secure investment to grow your business.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Venture - Series Unknown, Seed, Series A
- Geography: United Kingdom, United States, France
Investor stats
- Total investments: 291
- Round size: Seed $331k–$3.1M; Series A $1.7M–$7.5M; Venture - Series Unknown $199k–$4.1M
- Lead/follow: 13% lead, 87% follow
- Last fund: May invest from a new fund soon — last raise in 2015
Portfolio highlights
- Corvidae — Corvidae is a software company that provides data analysts, digital marketing, e commerce, and paid media solutions.
- IOTech — Discover IOTech Systems. Deploy, manage, and scale AI-driven, data-rich industrial systems at the edge with our open edge data platform.
- RoslinCT — We are the prefered global partner for cell and gene therapy solutions. With our wealth of expertise and infrastructure, we can support you at every step of your advanced therapy journey.
Inveready is a leading Spanish financial services firm focused on investment solutions and wealth management.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Venture - Series Unknown, Debt Financing
- Geography: Spain, United States, France
Investor stats
- Total investments: 284
- Round size: Seed $400k–$4.7M; Debt Financing $1.2M–$6.5M; Venture - Series Unknown $594k–$5.7M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely still investing — raised $63M in 2024
Portfolio highlights
- Mirai RiskTech — AI-driven balance sheet management for banks: ALM and liquidity, FTP, and regulatory reporting on one data model.
- Blinker — Blinker specializes in the wholesale of hardware.
- Connecta Therapeutics — Connecta Therapeutics is a biotechnology company that develops new treatments for unresolved medical needs of the central nervous system. It focuses on the development of a first-in-class drug for the treatment of fragile X syndrome.
Oxford Technology's SEIS fund and EIS fund enable private investors to access high growth technology startup opportunities and support UK innovation. SEIS and EIS tax reliefs offer downside protection, whilst gains can be tax free.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 112
- Round size: Seed $33k–$2.2M; Series A $786k–$8.5M
- Lead/follow: 8% lead, 92% follow
- Last fund: May invest from a new fund soon — last raise in 2012
Portfolio highlights
- OrganOx — OrganOx Limited was founded in 2008 to exploit normothermic preservation technology invented by Prof Peter Friend and colleagues and further developed by Prof Constantin Coussios at the University of Oxford.
- HydRegen — HydRegen is a biotechnology company that provides sustainable solutions for chemical manufacturing. HydRegen was founded in 2020 and was headquartered in Oxford, United Kingdom.
- Metacarpal — Metacarpal design upper-limb prosthetics without compromise. We aim to make the most robust, functional hand prosthesis that people love wearing because it works so effectively and looks so beautiful. Be proud to show your artificial side!
Discover Boehringer Ingelheim Venture Fund. We invest in groundbreaking science to transform care. Explore our mission and join us in advancing medicine
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, Germany, Switzerland
Investor stats
- Total investments: 108
- Round size: Seed $1.8M–$20M; Series A $3.8M–$34M; Series B $11M–$50M
- Lead/follow: 48% lead, 52% follow
- Last fund: May invest from a new fund soon — raised $250M in 2018
Portfolio highlights
- Tacalyx — Tacalyx develops therapeutics targeting cancer-specific carbohydrate antigens on the surface of metastatic malignant tumors where no satisfactory treatments exist.The name Tacalyx is derived from TACA (Tumor Associated Carbohydrate Antigen) and ‘lyx’ from the term Glycocalyx, the glycan-containing layer covering cells. Cancer cells differ fromnormal cells by displaying aberrant carbohydrate structures on their surfaces promoting metastasis, angiogenesis or suppression of the immune system. TACAs result from the aberrant glycosylation that is seen with transformation to a tumor cell and represent attractive targets for cancer treatment since they are displayed with high cancer specificity and enhance tumor virulence via the mentioned diverse mechanisms.
- smartbax — We develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
- Cloverleaf Bio — Cloverleaf Bio | Developing a new class of RNA therapeutics to revolutionize cancer therapy.
Almi Invest is Sweden’s most active early-stage venture capital firm, investing in scalable startups across Sustainability, Industry, Tech, and Life Science. We invest from pre-seed to Series A, always co-investing with independent private investors to accelerate innovation and long-term success. Our portfolio spans sustainable solutions, industrial innovation, deep tech, SaaS, and life science, supporting startups that drive economic and environmental progress. With €430 million under management and over 1,000 investments since 2009, we have backed leading companies like MIPS, Tobii, and Neo4j, with notable exits to Google, Apple, Microsoft, and Qlik. Beyond capital, we offer engaged ownership, providing strategic guidance, active board participation, and access to an extensive investor network. Almi Invest is part of the Almi Group and is funded by the European Regional Development Fund, Almi AB, and regional partners.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Venture - Series Unknown, Seed
- Geography: Sweden, Norway, United States
Investor stats
- Total investments: 552
- Round size: Seed $226k–$2.2M; Venture - Series Unknown $326k–$3.5M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely still investing — raised $64M in 2024
Portfolio highlights
- FirstQFM — FirstQFM is a Stockholm-based quantum technology company building proprietary foundation models for quantum computing.
- Ambidex AB — helps food retailers create new revenue streams on their refrigeration systems by stabilizing the electricity grid.
- Indevex AB — Indevex is a science-based and privately owned biotech company from Sweden. A natural and reliable partner, providing evidence based natural nutrition concepts based on the patented NGC™ Formula.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon DiscoveryGroup plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Spain
Investor stats
- Total investments: 63
- Round size: Seed $537k–$25M; Series A $4.5M–$50M; Series B $1.6M–$56M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- Quibim — Quibim builds AI tools that turn MRI, CT and PET data into actionable predictions for hospitals and biopharma. Trusted in 470+ centers worldwide.
- Nuclera — Nuclera offers a protein prototyping system to accelerate drug discovery by making proteins readily available to researchers. Nuclera's eProtein DiscoveryTM system allows scientists to rapidly produce and test proteins for drug discovery.
- 52 North Health — At 52 North we are developing fully-integrated clinical, AI and medical-device based systems.
The Center for Industrial Technological Development (CDTI) is a public corporation under the Ministry of Economy and Competitiveness, which promotes innovation and technological development of Spanish companies. Is the entity which channels requests for funding and support to projects I + D + i of Spanish companies in the national and international levels. The CDTI has a staff of more than 300 people formed three quarters of engineers and graduates. Although the bulk of the infrastructure of the CDTI is located in Madrid, the Centre offers Spanish companies a strategic network of offices and representatives abroad (Japan -SBTO (Spain Business and Technology Office) - Belgium -SOST (Spain Office of Science and Technology) and Permanent Secretariat Eureka-, Brazil -FINEP (Financier of Studies and Projects) -, Korea, Chile, Morocco, China, India, Mexico and USA) to support them in their technological activities of type int .
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Grant, Seed, Venture - Series Unknown
- Geography: Spain, United States, United Kingdom
Investor stats
- Total investments: 224
- Round size: Seed $576k–$5.8M; Grant $167k–$15M; Venture - Series Unknown $846k–$26M
- Lead/follow: 41% lead, 59% follow
Portfolio highlights
- MOA — MOA make healthy food for a sustainable world that solves growing global food demands. They are establishing a new industry of sustainable food that solves growing global food demands without the need for arable land. They are focused on designing high-value, natural and nutritious food.
- Anaconda BioMed — Anaconda Biomed, headquartered in Barcelona, Spain, is among the world's most innovative early stage medical technology companies. The company was founded by Dr. Ofir Arad and Dr. Marc Ribó in 2015, and is developing the ANCD BRAIN™, a novel 3rd Generation Stented Aspiration Thrombectomy System for the treatment of Acute Ischemic Stroke (AIS).
- Connecta Therapeutics — Connecta Therapeutics is a biotechnology company that develops new treatments for unresolved medical needs of the central nervous system. It focuses on the development of a first-in-class drug for the treatment of fragile X syndrome.
Transforming UK biotech breakthroughs into impact. o2h Ventures offers SEIS/EIS and growth-stage funds to back visionary teams from seed to clinical success.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Seed, Venture - Series Unknown, Series A
- Geography: United Kingdom, Hungary
Investor stats
- Total investments: 60
- Round size: Seed $603k–$7.3M; Series A $1.9M–$25M; Venture - Series Unknown $1.1M–$2.9M
- Lead/follow: 47% lead, 53% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Healx — Healx is a mission-driven technology company pioneering the next wave of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. There are 7,000 known rare diseases that affect 400 million people across the globe, but only 5% of those conditions have an approved treatment. By combining frontier AItechnology with deep drug discovery and development expertise, Healx can accelerate the pace, increase the scale and improve the chance of success of rare disease treatment development in order to meet this huge unmet need and have unprecedented patient impact. Founded in Cambridge, UK, in 2014 by Dr Tim Guilliams (a Biochemical Engineer and tech entrepreneur) and Dr David Brown (co-inventor of Viagra and former Global Head of Drug Discovery at Roche), Healx has raised $70 million to date. For more information, visit www.healx.io.
- Atelerix — Discover Atelerix's hypothermic hydrogels for reliable cell preservation and ambient temperature shipping. Ensure fresh, viable cell samples.
- Monument Therapeutics — Monument Therapeutics is a biotechnology company intended to develop drugs to treat serious diseases of the central nervous system.
IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and create value out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Information Technology
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Australia
Investor stats
- Total investments: 235
- Round size: Seed $208k–$7.6M; Series A $2.4M–$30M; Series B $7.9M–$68M
- Lead/follow: 22% lead, 78% follow
- Last fund: Likely actively investing — fresh fund, raised $50M in 2026
Portfolio highlights
- Eight19 — Eight19, located in Cambridge, UK, develops and manufactures plastic photovoltaics for energy harvesting, for the internet of things and for off-grid applications. Through the innovative use of industry-standard, high-volume, roll-to-roll processes and solution-based organic photoactive materials, the company has a highly cost-effective route forscaling-up its technology to supply the largest markets. Eight19 is currently producing modules on a small scale for commercial partners with applications in indoor energy harvesting for wireless sensor and controllers, signage and display, and outdoor power for portable electronics. Our plastic PV modules benefit from flexibility, thinness, light-weight and robustness.
- Matter Machine — Matter Machine is an AI-driven materials discovery company that creates technologies that use materials chemistry, machine learning, and automated experimentation to speed up the discovery and optimization of next-generation materials.
- Mach42 — Machine Discovery is a University of Oxford spin-out commercializing new machine learning technology. We leverage proprietary neural network technology to accelerate expensive calculations — and we do it with minimal data and 99.9% fidelity.
BioInnovation Institute is a biotechnology startup that offers entrepreneurs and researchers in life science. Early-stage life science start-ups are supported with up to 10 million DKK in funding, business acceleration, network, labs, and office space. It helps to early-stage start-ups within human health and planetary health. The startup's mission is to use its knowledge, network, funding, and infrastructure to incubate world-class life science and catalyze the commercialization of new solutions through start-ups. BioInnovation Institute was founded in 2018 and is based in Denmark.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Convertible Note, Pre-Seed, Seed
- Geography: Denmark, Germany, Switzerland
Investor stats
- Total investments: 93
- Round size: Seed $532k–$1.8M; Pre-Seed $530k–$5.2M; Convertible Note $495k–$1.6M
- Lead/follow: 92% lead, 8% follow
Portfolio highlights
- Visibuilt — Visibuilt develops sustainable, bio-based asphalt binders made from mycelium. Replace fossil bitumen with visiBIT.
- Agrobiomics — Agrobiomics is a danish Agritech start-up, harnessing the power of soil bacteria and their metabolites as new biostimulants to help crops cope with abiotic stress such as drought.
- metaLead Therapeutics — metaLead Therapeutics is to develop this peptide as a next-generation Pb poisoning treatment.
Verticals:Enterprise, SaaS, Security, Networks, AI, VR/AR, Marketplace, Blockchain, Internet of Things, New materials, Electronics, Robotics, Cleantech, Agrotech, Seatech, Therapeutics, Digital Health, Diagnostics, Innovative Accommodation, Tourist Entertainment Companies, Tour Operators, Wine, Nautical and Equestrian Tourism, Theme Parks Mobile, Robotics Founded in 2012, Portugal Ventures is a venture capital firm based in Porto, Portugal. The firm is a part of the Banco Português de Fomento group. The firm seeks to invest in pre-seed, seed and series A stages
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Venture - Series Unknown, Pre-Seed
- Geography: Portugal, United States, United Kingdom
Investor stats
- Total investments: 389
- Round size: Seed $121k–$1.9M; Pre-Seed $107k–$796k; Venture - Series Unknown $121k–$3.6M
- Lead/follow: 17% lead, 83% follow
- Last fund: May invest from a new fund soon — last raise in 2021
Portfolio highlights
- Aptoide — Find, discover and download the best apps and games for Android in the official Aptoide app store
- Unlockit — Unlockit will offer to public and governmental bodies the guarantee that everything within a real estate transaction is recorded, meaning better industry regulation, more taxes and public fees collected, and less overall fraud and money laundering activities.
- Outgoing — A ticketing tool that allows organizers to sell tickets directly on WhatsApp and Instagram. Users can purchase tickets through a personalized checkout process entirely within the chat, without registration or redirects. It also offers customer support that answers questions in real time.
IndieBio, re-named SOSV SF and SOSV NY in 2026, are two of SOSV’s three deeply resourced facilities for deep tech founders. The third is SOSV's HAX, in Newark, NJ. SOSV is the most active deep tech venture capital firm globally.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Pre-Seed, Convertible Note
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 676
- Round size: Seed $250k–$5M; Pre-Seed $50k–$525k; Convertible Note $150k–$950k
- Lead/follow: 3% lead, 97% follow
Portfolio highlights
- FluoSphera — Fluosphera better predicts the effects of molecules through animal-free microphysiological systems, helping you to discover more efficient drugs with less adverse side effects.
- Giraffe Bio — Giraffe Bio uses AI and biomolecules to optimize metal extraction, increase yield, and reduce environmental impact. Revolutionizing sustainable mining technology.
- Transition Metal Solutions — Transition harnesses wild microbial communities to recover copper and other critical metals from low-grade mining resources.
Impacting the future of medicine.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, The Netherlands
Investor stats
- Total investments: 229
- Round size: Series A $19M–$180M; Series B $16M–$155M; Series C $22M–$123M
- Lead/follow: 51% lead, 49% follow
- Last fund: Likely actively investing — fresh fund, raised $606M in 2026
Portfolio highlights
- OMass Therapeutics — OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics against challenging disease targets.
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
- Lisata Therapeutics — Lisata is a clinical-stage pharmaceutical company dedicated to improving lives through the discovery, development, and commercialization of innovative medicines.
Mercia Asset Management provides equity and debt to UK businesses with growth ambition. We are your investment partners from scale-up to exit.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Venture - Series Unknown, Series A
- Geography: United Kingdom, United States, Hungary
Investor stats
- Total investments: 148
- Round size: Seed $250k–$2.1M; Series A $1.3M–$14M; Venture - Series Unknown $394k–$5.3M
- Lead/follow: 68% lead, 32% follow
- Last fund: May invest from a new fund soon — last raise in 2013
Portfolio highlights
- Ben — Ben is the all-in-one platform for any company to personalise benefits and reward.Our secret? Marrying a modern software (SaaS) platform with per-employee Mastercards and financial infrastructure. That’s how Ben instantly adds employee choice to your existing benefits, unlocks access to hundreds of additional options through Ben Card, all whilesaving you time and money.
- Distil.ai — Distil.ai is a software platform that helps businesses to understand their customers’ behavior and identify buying signals.
- MRC Engineering — MRC Engineering Providing a different option to the UK Rail Industry for Telecoms Design. Nationally renowned design specialists who provide extraordinary ...
We are a leading tech investor & venture builder in the Nordics. Taking deep tech from lab to market.WELCOMEINVESTMENTS
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Pre-Seed, Seed, Venture - Series Unknown
- Geography: Sweden, United States
Investor stats
- Total investments: 282
- Round size: Seed $237k–$2.3M; Pre-Seed $5.8k–$349k; Venture - Series Unknown $357k–$3.5M
- Lead/follow: 45% lead, 55% follow
Portfolio highlights
- Ambidex AB — helps food retailers create new revenue streams on their refrigeration systems by stabilizing the electricity grid.
- Solinide Photonics — Solinide Photonics is a technological company spun out of Chalmers University of Technology. It develops ultra-efficient silicon nitride-based photonic circuits and microcomb technologies.
- InfiniNode Technologies AB — InfiniNode is a semiconductor IP company that seeks to enable efficient data movement in future compute systems.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!GO Capital is an independent management company and a major player in regional Seed and Venture Capital since 2003. With offices in Brittany, Pays de la Loire, Normandy, Centre-Val de Loire and the South of France, GO Capital contributes to the financing of responsible innovation in these regions. With a team of investors with complementary sectoral experience, we have a solid track-record in DeepTech. GO Capital has nearly 400 million euros under management, and mainly finances technology leaders in the digital and healthcare sectors and in the industry of the future.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Venture - Series Unknown, Series A
- Geography: France, Canada, Israel
Investor stats
- Total investments: 144
- Round size: Seed $549k–$7.1M; Series A $2.1M–$13M; Venture - Series Unknown $974k–$9.5M
- Lead/follow: 40% lead, 60% follow
- Last fund: Likely still investing — raised $25M in 2023
Portfolio highlights
- SoonGo — SoonGo is a SaaS company that helps businesses manage and optimize vehicle fleets and professional mobility using data and AI.
- Edison IA — Edison IA functions as an artificial intelligence accelerator designed to help small and medium-sized enterprises integrate AI into their business operations. The company provides a structured, multi-phase framework—spanning 30, 60, and 90 days—to guide businesses from initial training to full deployment. It specializes in developing custom, secure AI agents tailored to automate internal processes, analyze data, and optimize specific corporate workflows. Their service includes auditing a company's readiness, training employees, and implementing scalable AI solutions that comply with data privacy standards.
- NeoXperiences — NeoXperiences develops technological solutions that bring audiences together around fun and interactive experiences.
BGF is the most active equity investor in the UK and Ireland, providing long-term, minority investment to growing companies.
Show more...Investment focus
- Industry: Software, Manufacturing, Information Technology
- Stage:Venture - Series Unknown, Private Equity, Series A
- Geography: United Kingdom, Ireland, United States
Investor stats
- Total investments: 608
- Round size: Series A $4.1M–$21M; Private Equity $6.4M–$22M; Venture - Series Unknown $3.4M–$16M
- Lead/follow: 86% lead, 14% follow
- Last fund: Likely still investing — raised $97M in 2022
Portfolio highlights
- Camino — Camino Leisure Holdings is a Spanish bar and restaurant that serves authentic food and wines.
- Arran Aromatics —
- Boost Juice Bars UK — Boost Juice Bars UK offer a range of smoothies and freshly squeezed juice products.
European Investment Bank operates as the lending institution of the European Union, offering loans, guarantees, and technical expertise to governments, businesses, and financial institutions. The organization focuses on areas such as climate action, digital transformation, housing development, and security-related initiatives. Its activities include funding large-scale infrastructure, supporting technology development, and facilitating access to capital for emerging and established enterprises. The bank also delivers advisory support to structure projects, improve investment readiness, and align initiatives with policy objectives.
Show more...Investment focus
- Industry: Energy, Biotechnology, Health Care
- Stage:Debt Financing, Post-IPO Debt, Venture - Series Unknown
- Geography: France, Germany, Italy
Investor stats
- Total investments: 600
- Round size: Post-IPO Debt $16M–$587M; Debt Financing $16M–$370M; Venture - Series Unknown $8.7M–$110M
- Lead/follow: 83% lead, 17% follow
Portfolio highlights
- RougeTx — RougeTx is a Netherlands-based biotech developing first-in-class small-molecule therapies for vascular diseases caused by pericyte dysfunction. Its lead candidate, RTX-001, targets hereditary haemorrhagic telangiectasia (HHT), an inherited disorder involving fragile blood vessels and recurrent bleeding.
- MedinCell — Join Medincell on a journey to transform global health with innovative therapies.
- Santander Brasil — Banco Santander in Brazil, its largest division in Latin America and one of the world's most important, accounting for 50%.
Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets. Its international team is led by Sinclair Dunlop, Kyp Sirinakis and Liz Roper. With offices in the United States and United Kingdom Epidarex Capital’s investors represent a cross-section of leading universities, international corporations, development agencies and financial institutions. Epidarex was created to meet the need for more sector-specific financial backing for young companies, including spin-outs from leading research universities.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 53
- Round size: Seed $551k–$8.5M; Series A $2.6M–$40M; Series B $2.4M–$48M
- Lead/follow: 45% lead, 55% follow
- Last fund: Likely actively investing — fresh fund, raised $145M in 2026
Portfolio highlights
- Mironid — Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network.
- RougeTx — RougeTx is a Netherlands-based biotech developing first-in-class small-molecule therapies for vascular diseases caused by pericyte dysfunction. Its lead candidate, RTX-001, targets hereditary haemorrhagic telangiectasia (HHT), an inherited disorder involving fragile blood vessels and recurrent bleeding.
- Epsilogen — IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.
The team behind Catapult Ventures are among the most experienced venture capital investors in the UK. Their experience spans a range of sectors from healthcare and pharmaceuticals to luxury consumer brands, manufacturing and software, as well as all stages: from start-ups and pre-revenue IP developers to company floatation and billions of pounds in revenue. Their administration team is equally experienced with each member having more than 10 years experience in a venture capital environment.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Venture - Series Unknown
- Geography: United Kingdom, United States, Israel
Investor stats
- Total investments: 105
- Round size: Seed $150k–$5.6M; Venture - Series Unknown $370k–$5M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — last raise in 2018
Portfolio highlights
- Path Robotics — We create manufacturing robots that autonomously scan, position, and weld your parts without the need for skilled welders or robot programmers.
- Pickle Robot — We make robots that unload trucks without retrofitting the warehouse
- Anello Photonics — Anello Photonics is a technology company developing a silicon photonic optical gyroscope to navigate, position, and motion track autonomous applications in challenging GPS-jammed and spoofed environments. The company's technology portfolio spans over 28 issued patents, and over 44 pending patents, and includes an AI-based sensor fusion engine.It serves the robotics, defense, construction, agriculture, and autonomous vehicles industries.
Noshaq offers financial services to help businesses develop.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed, Venture - Series Unknown
- Geography: Belgium, France, Germany
Investor stats
- Total investments: 82
- Round size: Seed $137k–$6M; Series A $3.6M–$16M; Venture - Series Unknown $2M–$16M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- Le Fourgon — Le Fourgon provides contained drinks for home delivery. They offer milk, water, beer, wine, fruit juice, and sodas. They allow customers to have their drinks delivered free of charge during the day.
- Allegro Biotech — Allegro has developed the world’s-first custom-tailored, durable, biocompatible, anisotropic, regenerative meniscus cartilage, providing immediate support while also leverage the body’s own healing potential to regenerate human cartilage (proliferation and differentiation of fibrochondrocyte cells).
- Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
Development Bank of Wales is an independent company, providing commercial funding to Welsh SMEs. They invests private and public funds, including EU funds.
Show more...Investment focus
- Industry: Software, Health Care, Manufacturing
- Stage:Seed, Debt Financing, Venture - Series Unknown
- Geography: United Kingdom, Australia, United States
Investor stats
- Total investments: 296
- Round size: Seed $279k–$3M; Debt Financing $19k–$3.7M; Venture - Series Unknown $383k–$5.5M
- Lead/follow: 61% lead, 39% follow
- Last fund: May invest from a new fund soon — raised $27M in 2018
Portfolio highlights
- Reacta Biotech — Reacta Biotech has been established to develop, manufacture and commercialise oral food challenge materials to pharmaceutical standards of Good Manufacturing Practice (GMP).
- MeOmics Technology — MeOmics Technology is a biotech company with a focus on improving the diagnosis and treatment of mental health illnesses. The company operates in the manufacturing industry and has a team of 9 employees. The team includes experts in Neuronal Cell Biology and Neuropsychopharmacology. The company's mission is to leverage technology to enhancethe understanding and treatment of mental health conditions.
- Outlook Expeditions — Outlook Expeditions provide overseas educational expeditions, adventure travel and service-learning projects for schools.
HAX is a program for Hard Tech startups taking their first steps towards commercialization. We provide hands-on support and investment as part of SOSV, a $1B AUM multi-stage venture firm.
Show more...Investment focus
- Industry: Robotics, Manufacturing, Health Care
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, Canada, China
Investor stats
- Total investments: 669
- Round size: Seed $100k–$4.7M; Pre-Seed $25k–$2.4M; Convertible Note $100k–$3.8M
- Lead/follow: 1% lead, 99% follow
Portfolio highlights
- 5QXT — 5QXT is a mining technology company that provides the design, development, and implementation of metal extraction processes.
- XFuel — XFuel is a fuel company that provides green and clean fuels to distributors and consumers. The company was founded in 2010 and is based in Palma de Mallorca, Baleares.
- Cortysis — Cortysis develops brain stimulation device for rapid spatial and temporal modulation of cortical networks
Northstar Ventures invests venture capital in early and later stage, high growth companies tackling global challenges, focusing on climate tech and healthy ageing.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Seed, Venture - Series Unknown, Series A
- Geography: United Kingdom, United States, Indonesia
Investor stats
- Total investments: 280
- Round size: Seed $46k–$1.4M; Series A $295k–$10M; Venture - Series Unknown $261k–$3.8M
- Lead/follow: 25% lead, 75% follow
- Last fund: Likely still investing — raised $20M in 2024
Portfolio highlights
- OneClickComply — OneClickComply automates ISO 27001, SOC 2, Cyber Essentials and 240+ standards: evidence from 13,000+ tools, one-click fixes and an in-house audit team.
- Land Digital — Land Digital is a tech, web design, web creation, content marketing, digital marketing, SEO, and mobile application agency.
- Magnitude Biosciences — Magnitude Biosciences is a biotechnology firm combine experience in ageing research, the nematode C. elegans and automation.
Idinvest Partners is a pan-European private equity manager focused on the low and middle-market segments. With over 6 billion euros under management, the company has developed several complementary areas of expertise, including equity investments in buyout deals focusing on both mid-size as well as young innovative European companies; primary investments in European private equity funds focusing primarily on the middle market segment; secondary investments; mezzanine investments in Europe; and private equity consulting. Idinvest Partners’ recent success stories include Criteo, Clear2Pay, Meetic, Prosensa, Converteam, Kwik Fit, Lastminute.com, Dailymotion, Deezer, Talend, Synthesio, Menlook, Vestiaire Collective, Pretty Simple, Curse.com, Withings, Kantox, Secret Escapes, Happn, Peakon, Dayuse, Botify, Financefox, Azalead and many more.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Series B, Venture - Series Unknown
- Geography: France, United States, Germany
Investor stats
- Total investments: 351
- Round size: Series A $3.4M–$22M; Series B $7.8M–$66M; Venture - Series Unknown $4.1M–$37M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $97M in 2021
Portfolio highlights
- Actility — Actility provides IoT connectivity and solutions to power smart cities and industries.
- Pretty Simple — Video games studio based in Paris, France. Makers of Criminal Case and Sorcery School.
- StarTower — StarTower is a resource company built specifically for fully decentralized physical infrastructure and shared interaction. Based on the exclusive RIP encryption technology, StarTower realizes the interactive sharing of multiple resources with zero loss on mobile devices, thereby providing efficient resource transmission for terminal facilities. Itprovides more efficient, secure and reliable solutions in the fields of Internet of Things, smart cities, industrial automation, healthcare, etc.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Karista is an early-stage venture capital firm created in 2001 investing in Health, Digital, Tech, and NewSpace.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A, Series B
- Geography: France, United States, Finland
Investor stats
- Total investments: 162
- Round size: Seed $768k–$6.2M; Series A $1.4M–$23M; Series B $3M–$33M
- Lead/follow: 18% lead, 82% follow
- Last fund: Likely still investing — raised $44M in 2021
Portfolio highlights
- Kynogon — Autodesk game middleware products, including Beast, Navigation, HumanIK and Scaleform, will no longer be available for purchase.
- Advestigo — Advestigo S.A., a technology company, provides digital assets protection solutions. It offers theraography technology, which analyses digital content to generate content-based fingerprints; AdvestiCHECK, a software package that allows companies to monitor information technology networks and workstations; and AdvestiGUARD, a software package thatallows companies to monitor communication channels. The company was founded in 2002 and is based in Saint-Cloud, France. As of March 9, 2009, Advestigo S.A. operates as a subsidiary of Hologram Industries SA.
- Plasmabiotics — PENTAX Medical PlasmaBiotics: Ultra-fast endoscope reprocessing solutions to improve patient safety and infection prevention.
Elaia is French venture capital firm focused on European digital and deep tech startups, from early stage to growth developpement. We back tech disruptors.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Series A, Series B
- Geography: France, United States, Spain
Investor stats
- Total investments: 241
- Round size: Seed $1.1M–$7.6M; Series A $2.7M–$23M; Series B $4.2M–$50M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely actively investing — fresh fund, raised $154M in 2026
Portfolio highlights
- Hema.to — Flow cytometry analysis software, re-imagined. From raw FCS and LMD data to finalized report with AI-powered CellStudio.
- RelaiSanté — RelaiSanté provides a digital coordination platform that connects hospitals with home care providers to manage patient return home. The company offers online tools for hospital teams, home help services, independent nurses and territorial health actors to organize care pathways after hospitalization. RelaiSanté enables secure information sharing, task assignment and monitoring of care arrangements between medical and social care stakeholders. Its products include dedicated interfaces for establishments, home care services and independent professionals. The platform supports teams in structuring discharge processes, reducing fragmentation of communication and clarifying responsibilities. RelaiSanté focuses on improving continuity of care between the healthcare facility and the patient’s home environment.
- Sim&Cure — Providing Physicians with advanced endovascular treatment solutions for a better Patient Care
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by great entrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 189
- Round size: Seed $2.4M–$24M; Series A $5.8M–$56M; Series B $13M–$100M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- Mueon — semiconductor-based systems for AI and hyperscale computing
- iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
- Polaris Electro-Optics — Polaris Electro-Optics empowers integrated photonics for communications and computation.
Syncona is a FTSE250 company focused on founding, building and funding healthcare companies to deliver transformational treatments to patients in areas of high unmet need.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A, Series B, Seed
- Geography: United Kingdom, United States, Switzerland
Investor stats
- Total investments: 78
- Round size: Seed $1.9M–$17M; Series A $13M–$87M; Series B $29M–$156M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- OMass Therapeutics — OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics against challenging disease targets.
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
- Re-Aim Therapeutics — Re‑Aim Therapeutics is a UK‑based biotech start‑up developing functional cures for T cell–mediated autoimmune diseases by selectively depleting pathogenic T‑cell subsets. Its lead asset, REA‑001, is a monoclonal antibody designed to potently and precisely eliminate disease‑causing type‑17 T cells, aiming to reset the immune system and achievedurable, treatment‑free remission in multiple autoimmune conditions.
Kelvin Capital was founded in 2009 and has since raised a total of over £50million into 28 portfolio companies. We invest venture capital in revenue generating growth companies which have the potential to deliver significant return to their investors. They also invest in companies that require capital to grow their business. For the right companywith the right team, Kelvin Capital provides the investment and the support needed to deliver the true potential of their business.The Kelvin Capital team has a combined 30 years experience of working with new businesses and understands both the challenges and opportunities, which will be encountered during the high growth phase. The team has built up extensive networks, which will be made available to assist and support the portfolio businesses. Kelvin Capital will actively promote the portfolio businesses through its website and social media activities raising their awareness and profile. The entire Kelvin Capital team is focused on the success of their portfolio of businesses.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Manufacturing
- Stage:Seed, Venture - Series Unknown
- Geography: United Kingdom, United States
Investor stats
- Total investments: 111
- Round size: Seed $167k–$1.9M; Venture - Series Unknown $485k–$4.5M
- Lead/follow: 47% lead, 53% follow
Portfolio highlights
- Kenoteq — Discover Kenoteq, pioneering the sustainable construction revolution with our innovative, ultra low-carbon building materials.
- Aurora Avionics — Accelerating launch-vehicle development with flexible and modular avionics platforms.
- Sofant Technologies — Sofant is developing a low cost RF MEMS technology that solves power consumption and heat problems in high frequency phased array antenna systems.
CDP Venture Capital Sgr - National Innovation Fund aims to make venture capital a cornerstone of the country's economic development and innovation, creating the conditions for an overall and sustainable growth of the venture capital ecosystem.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Italy, United States, Switzerland
Investor stats
- Total investments: 302
- Round size: Seed $483k–$8.1M; Series A $3.3M–$23M; Venture - Series Unknown $652k–$17M
- Lead/follow: 41% lead, 59% follow
- Last fund: May invest from a new fund soon — raised $212M in 2021
Portfolio highlights
- Evja — Evja supports growers in optimizing the management and monitoring of irrigation, nutrition and protection of their crops through the use of OPI, the most advanced system for precision agriculture .
- TrueLayer — We power faster and safer online payments with our open banking payments network. Onboard users, accept payments & make payouts in seconds. Learn more today.
- Tretau — E-mobility is powered by its core - the electric motor. We at Tau are at the very core of the core: the copper winding wire, the magnetic core, the electrical steel.We just make it bet.
Established in 1992. Archangels is the oldest continuously operating business angel syndicate in the World. Investing in IP-rich tech & life sciences companies in Scotland, UK.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Venture - Series Unknown, Seed
- Geography: United Kingdom, United States
Investor stats
- Total investments: 88
- Round size: Seed $1.3M–$6.6M; Venture - Series Unknown $867k–$6.3M
- Lead/follow: 53% lead, 47% follow
Portfolio highlights
- CSignum — Revolutionising underwater communications with electromagnetic technology for seamless data integration between surface & submerged devices.
- Corvidae — Corvidae is a software company that provides data analysts, digital marketing, e commerce, and paid media solutions.
- iGii — Integrated Graphene enable better products with a revolutionary design for manufacture process producing the world's highest quality pure 3D Graphene Foam, Gii.
Do and dare company
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A, Series B
- Geography: Belgium, United States, The Netherlands
Investor stats
- Total investments: 161
- Round size: Seed $1M–$4.1M; Series A $3M–$40M; Series B $6.6M–$43M
- Lead/follow: 22% lead, 78% follow
Portfolio highlights
- Logibot — Logibot is a European, software-first, hardware-agnostic AI platform that enables logistics and industrial operators to simulate, deploy, and operate human-like robotic labor inside existing intralogistics facilities, without vendor lock-in and without rebuilding the warehouse. Most warehouse automation projects fail because they assume greenfield sites or commit operators to one robot vendor. Logibot takes a different approach. Operators start with Logibot.Data to quantify manual work and score automation feasibility. Logibot.Simulate runs split tests on multiple robot configurations in digital simulation, before any hardware decision is made. Logibot.Train prepares a general vision-language model for specific logistics tasks in five stages. Logibot.Control stages the introduction of robotic labor into live operations. Logibot.Watch provides real-time monitoring, teleoperation, and continuous improvement. Logibot serves 3PLs, CEP operators, postal operators, and industrial logistics teams. Headquartered in Belgium, operating across the EU. NVIDIA Inception member. Beam Berlin portfolio company.
- Borro — Cashless deposit system
- SpectaCell — SpectaCell is a Belgian life sciences and biotechnology company that develops next-generation cell therapy analytics.Spun out of a collaborative research effort between imec, VIB, and Ghent University (UGent),
Invivo Capital is a team of knowledgeable professionals with the scientific, technical, and financial know-how required to analyze and make investments that provide value to the invested company. They also have a network of contacts and key strategic relationships in the health ecosystem.
Show more...Investment focus
- Industry: Biotechnology, Pharmaceutical, Health Care
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Spain, France, Belgium
Investor stats
- Total investments: 35
- Round size: Seed $1.6M–$13M; Series A $2.2M–$70M; Venture - Series Unknown $3.3M–$8.9M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $44M in 2019
Portfolio highlights
- Signadori Bio — Signadori Bio is the next-generation cellular immunotherapy for cancer cure.This has culminated in the creation of a groundbreaking biotech venture in the cell and gene space that is set to advance innovative approaches in oncology.
- ARTHEx Biotech — ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing advanced RNA treatments against genetic diseases.
- Telum Therapeutics — Telum Therapeutics is a biotechnology company that develops new treatments for infectious diseases based on the use of lytic enzymes from bacteriophages.
We provide venture capital investment for the people, ideas and industries that will change the world. Learn about what we do and the kind of founders we back.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Series A, Seed, Series B
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 442
- Round size: Seed $2.1M–$12M; Series A $3.4M–$22M; Series B $8M–$43M
- Lead/follow: 56% lead, 44% follow
- Last fund: May invest from a new fund soon — raised $108M in 2019
Portfolio highlights
- Grasp — Grasp is the world's first AI analyst for finance professionals. Our AI analyst automates company and market research for investment banks, private equity firms, and management consulting firms across the world.
- Living Optics — Living Optics is commercializing next generation imaging technology which leverages a compact camera system based on breakthroughs in hardware design and software processing.
- Monkey Bizness — Monkey Bizness is the largest provider of indoor family entertainment centres in the UK. Each centre includes a children's soft play area and is designed to provide a safe, clean and fun environment in which parents and children can feel comfortable. Monkey Bizness' centres provide a setting that encourages children to express themselvesthrough creativity and play as well as providing fresh and nutritious food to keep kids happy and healthy.Monkey Bizness currently has centres in eight locations: Lewes, Gosport, Poole, Sheffield, Stevenage, Hull Edinburgh and Glasgow.
FAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotech Investors in Europe investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 48,091 investors investing in Europe Biotech startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!